4 Biotechnology Stocks to Buy Now

by Portfolio Grader | January 16, 2013 4:00 pm

This week, four Biotechnology stocks are improving their overall rating on Portfolio Grader[1]. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, Aegerion Pharmaceuticals (NASDAQ:AEGR[2]) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. Shares of AEGR have increased 21.5% over the past month, better than the 4.7% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of AEGR stock[3].

Gentium (NASDAQ:GENT[4]) shows solid improvement this week. The company’s rating rises from a B to an A. Gentium is a biopharmaceutical company focused on the discovery, research, development, and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. For more information, get Portfolio Grader’s complete analysis of GENT stock[5].

Novavax’s (NASDAQ:NVAX[6]) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Novavax creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. Wall Street seems to agree with the upgrade and has propelled the stock up 14.4% over the past month. For more information, get Portfolio Grader’s complete analysis of NVAX stock[7].

This week, China Biologic Products’ (NASDAQ:CBPO[8]) ratings are up from a B last week to an A. China Biologic Products is a biopharmaceutical company that engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 25.5% over the past month. For more information, get Portfolio Grader’s complete analysis of CBPO stock[9].

Louis Navellier’s proprietary Portfolio Grader[10] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[11].

Endnotes:
  1. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  2. AEGR: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=AEGR
  3. For more information, get Portfolio Grader’s complete analysis of AEGR stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=AEGR
  4. GENT: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GENT
  5. For more information, get Portfolio Grader’s complete analysis of GENT stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GENT
  6. NVAX: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=NVAX
  7. For more information, get Portfolio Grader’s complete analysis of NVAX stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=NVAX
  8. CBPO: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CBPO
  9. For more information, get Portfolio Grader’s complete analysis of CBPO stock: http://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CBPO
  10. Portfolio Grader: http://navelliergrowth.investorplace.com/portfolio-grader/
  11. here: http://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: http://investorplace.com/2013/01/4-biotechnology-stocks-to-buy-now-aegr-gent-nvax/
Short URL: http://invstplc.com/1nDuofi